v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses    
Research and development $ 9,334 $ 4,074
General and administrative 5,521 3,797
Total operating expenses 14,855 7,871
Operating loss (14,855) (7,871)
Other (expense) income:    
Interest expense - royalty agreement (2,039) (1,215)
Fair value adjustments on derivative liabilities - royalty agreement (116) (75)
Fair value adjustments on derivative liabilities - contingent value right liability 202 0
Interest income, net 1,073 752
Other income (expense), net (32) 224
Loss before income taxes (15,767) (8,185)
Income tax benefit (expense) 0 0
Net loss (15,767) (8,185)
Other comprehensive loss:    
Unrealized gain on investments 4 0
Foreign currency translation gain (loss) 8 (6)
Comprehensive loss $ (15,755) $ (8,191)
Net loss per share of Common Stock - basic (in dollars per share) $ (1.2) $ (0.74)
Net loss per share of Common Stock - diluted (in dollars per share) $ (1.2) $ (0.74)
Weighted-average shares used in computing net loss per share of Common Stock - basic (in shares) 13,085,271 11,013,697
Weighted-average shares used in computing net loss per share of Common Stock - diluted (in shares) 13,085,271 11,013,697